Leiomyosarcoma (LMS) Cancer
What Is Leiomyosarcoma?
Leiomyosarcoma is a malignant (cancerous) tumor derived from smooth muscle cells. Otherwise known as LMS, leiomyosarcoma tumors are considered rare and often difficult to treat. The prognosis is poor, and survival rates are among the lowest out of all soft tissue sarcomas.
Leiomyosarcoma (LMS) is one form of a very rare and aggressive cancer called ‘sarcoma,’ which is a cancer of the connective or supportive tissues of the body. These tissues can be found in bone, cartilage, fat, muscle, and blood vessels. Among uterine cancer patients, uterine leiomyosarcomas (ULMS) account for roughly one percent of patients with uterine cancer. It is worth noting that leiomyosarcoma can arise from other gynecological primary sites.
Leiomyosarcomas can be quite unpredictable. In some patients, they can remain dormant for long periods of time only to recur after a few years. Leiomyosarcoma is considered a resistant cancer, which means it generally doesn’t respond to chemotherapy or radiation. The best reported outcomes occur when the tumors can be surgically removed with wide margins in an early stage, while small and still in their original place (when malignant cells are present as a tumor but have not yet metastasized beyond the basement membrane of where the tumor was first discovered).
Leiomyosarcoma Symptoms
Uterine leiomyosarcoma is most common among women between the ages of 40 and 60 years of age.
Some of the most frequent presenting symptoms include:
- Abnormal vaginal bleeding (amount of bleeding can vary from spotting to menorrhagia (abnormal heavy bleeding during menstruation)
- Pelvic or abdominal pain
- Foul-smelling vaginal discharge
Less common symptoms can include:
- Weight loss
- Weakness
- Lethargy
- Fever
In a pelvic exam, the uterus is often enlarged and in some cases, part of the tumor can prolapse through the cervical os (the opening of the cervix) into the vaginal canal. Diagnosis of ULMS is generally not made prior to surgery, so many patients see a physician with advanced disease.
Leiomyosarcoma Prognosis
According to a recent study published in the International Journal of Surgical Oncology (Volume 2014), uterine leiomyosarcoma carries an extremely poor prognosis. Selected patients who had greater than a year of first recurrence, resectable disease (surgically removable) at recurrence, and early stage of the disease at initial diagnosis, a secondary cytoreductive surgery can be beneficial and may prolong survival.
Leiomyosarcoma and Fibroids
Uterine fibroids are noncancerous tumors in the uterus that often appear in women during their childbearing years. Also referred to as leiomyomas, uterine fibroids are not associated with a higher risk of uterine cancer and rarely develop into cancer.
Fibroids form in the smooth muscular tissue of the uterus (called the myometrium). Their growth can be unpredictable, with some fibroids staying the same size and others going through growth spurts. In some cases, uterine fibroids may shrink on their own. Fibroids present during pregnancy can shrink or disappear outright after pregnancy, as the uterus returns to a normal size.
As many as 75 percent of women will have uterine fibroids at some point in their lives, though many are unaware of their presence, as they often do not cause symptoms.
Uterine Fibroids (Leiomyomas) | Leiomyosarcoma |
Usually multiple | Often solitary |
White | Yellow or tan |
Varying in size, but usually 3-5cm | Large, often >10cm |
Firm surface | Soft, fleshy cut surface |
Hemorrhage and necrosis infrequent | Hemorrhage and necrosis frequent |
Leiomyosarcoma, on the other hand, is rare and carries with it a poor prognosis. Doctors who evaluate women with presumed uterine fibroids are challenged when deciding which rare patients may have leiomyosarcoma. While there are differences in the populations, there is some overlap between the two disorders.
Leiomyosarcoma after Hysterectomy
According to the Food and Drug Administration, about one in every 350 women undergoing a fibroid removal procedure have undetected cancer cells. These cells can easily be seeded throughout the pelvic and abdominal cavity if a power morcellator is used during hysterectomy or myomectomy.
Leiomyosarcoma Treatment
Leiomyosarcomas are considered aggressive tumors, often difficult to treat. A multi-specialty treatment team at a specialized sarcoma care center is a patient’s best option for treatment.
Surgery
Local control of soft tissue sarcomas is often achieved with surgery. Pre-operative planning is necessary to ensure adequate surgical margins. Having wide surgical margins is essential to preventing recurrence.
Radiation Z
If a wide surgical margin is not possible, radiation therapy can be an important additional treatment used to improve rates of local control, especially in sarcomas that have reached a high grade. Radiation can either be delivered pre-operatively or post-operatively.
Chemotherapy
Chemo can help slow the progress of leiomyosarcoma. At present, there are a number of investigational studies looking at other potential agents that could be useful in the treatment of leiomyosarcoma. Chemo is occasionally used after initial treatment for cancer, especially to suppress secondary tumor formation.
Leiomyosarcoma Survival Rate
Stage | 5-Year Survival Rate |
Localized | 63% |
Regional | 36% |
Distant | 14% |
OVER $4 billion
in verdicts & Settlements
Our top priority is to devise customized legal strategies that are tailored to the unique legal needs of our clients, no matter how simple or complicated their situations, might be.
-
$265 Million Settlement Fatal Train Crash
In 2016, Wisner Baum attorney Timothy A. Loranger and six other attorneys in the Plaintiffs’ Management Committee were able to secure a $265 million settlement for victims of the 2015 Amtrak 188 derailment in Philadelphia, one of the largest in the U.S. for 2016.
-
$14 Million Settlement A Major US Plane Crash
Wisner Baum obtained a $14 million settlement for the death of a passenger in a major US plane crash.
-
$12 Million Settlement Helicopter Crash
Wisner Baum secured a $12 million settlement for a passenger who was injured in a helicopter crash.
-
$10 Million Settlement A Major Foreign Plane Crash
Wisner Baum obtained a $10 million settlement for the death of a passenger in a major foreign plane crash.
-
$2.0 Billion Verdict Personal Injury
In May of 2019, the jury in the case of Pilliod et al. v, Monsanto Company ordered the agrochemical giant to pay $2.055 billion in damages to the plaintiffs, Alva and Alberta Pilliod, a Bay Area couple in their 70s.
Our Case Results
-
$10 Million Settlement A Major Foreign Plane Crash
Wisner Baum obtained a $10 million settlement for the death of a passenger in a major foreign plane crash.
-
$14 Million Settlement A Major US Plane Crash
Wisner Baum obtained a $14 million settlement for the death of a passenger in a major US plane crash.
-
$17.5 Million Settlement A Major US Plane Crash
Wisner Baum obtained a $17.5 million settlement on behalf of a client who was killed in a major U.S. plane crash.
-
$10 Million Settlement Celexa-Lexapro Pediatric Class Action
$10 million pediatric class action re false promotion of Celexa and Lexapro. Babies born to women who have used Lexapro and other similar medications such as Zoloft, Celexa, Prozac, Paxil, and Symbyax are at an increased risk for birth defects.
-
$8.5 Million Verdict Commercial Truck Accident
Wisner Baum secured a $8.5 million wrongful death verdict against the food industry company, Tyson Foods, for the wrongful death of a young man.
-
$28 Million Settlement Defective Drug Class Action
$28 million Paxil defective drug class action. A class action has been brought in the US territory of Puerto Rico against UK-based drug major GlaxoSmithKline.
Client-Focused Representation
REVIEWS & TESTIMONIALS
We believe our track record speaks for itself. But you don’t have to take our word for it. See what our clients have to say about working with us.
-
"I Can’t Imagine a Better Law Firm"
Multiple lawyers recommended Wisner Baum to me and I have been consistently impressed with the quality of their work.
- Best Law Firms Survey -
"They Are About Changing the Systems..."
Wisner Baum are not only amazing attorneys but more importantly, they are activists. They are about changing the systems which got us into trouble in the first place. They understand their role in the process of making change.
- Kim Witczak -
"Top Legal Minds in the Country"
The Wisner Baum firm has some of the top legal minds in the country; they are driven, determined, trustworthy, ethical and passionate.
- From Best Lawyers® Best Law Firms
